A&R: Climate Emergency and the Health of Our Patients - A public health crisis that will affect Rheum pts - climate factors can worsen Dz - Pollution causes autoimmunity - Climates worse effects on the vulnerable - Advocacy solutions research are needed https://t.co/JJufiImhND

Efgartigimod Treatment in Chronic Primary ITP https://t.co/iJMeG2CJJv https://t.co/OXE7CuScBC

Substandard Therapy in RA Clinicians could improve outcomes in their patients w/ RA by paying attention to certain markers of care quality, like early referral to certified rheumatologists and prescribing standard drugs for RA, new research suggested. https://t.co/Ln6XQHLVJE https://t.co/454Ff8dEr8

Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease. https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL

NIH has granted $4.7 million to fund OHSU/UAB/UNC scientists to develop Novel 2-Pyrimidone (SRI-42718) Chikungunya antiviral drug. 2022: >360,000 Chikungunya cases w/ 77 deaths (mostly Brazil, India Guatemala) w/ 13 acquired in U.S. https://t.co/5ospHoFBBQ https://t.co/E1WKvdhaUO

Swedish study of 4033 incident RA vs 6485 controls - Exposure to occupational inhalable increased risk ACPA+ RA (OR 1.25). Occupational inhalable agents plus smoking and shared epitope markedly elevated risk (OR 18.22) esp in ACPA+RA https://t.co/4lKLEhkURm https://t.co/HFhz8lMR10

Study of 172 febrile pts w skin rash + arthralgia; 112 Dx w/ #AOSD. Use of a "streamlined diagnostic process (looking @ neutrophilia, hyperferritinemia, high IL-18), shortened Dx time (2 vs 4 wks), earlier Dx and more remissions (85% vs 68%, p < 0.05) https://t.co/MSMq2XLeYA https://t.co/ECKkeVqTIW

Biosimilar Bonanza in 2023 Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow https://t.co/FILyCcSThn https://t.co/kBxzZgs6rM